Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease.

Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K.

Cancer Manag Res. 2018 Dec 14;10:7013-7019. doi: 10.2147/CMAR.S189556. eCollection 2018.

2.

Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.

Araya T, Kita T, Ueda T, Terada N, Sakai T, Yamamura K, Kurokawa K, Uchida Y, Sone T, Kimura H, Kasahara K.

Can Respir J. 2019 Mar 20;2019:5315903. doi: 10.1155/2019/5315903. eCollection 2019.

3.

Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.

Niwa H, Nakahara Y, Yokoba M, Mitsufuji H, Sasaki J, Masuda N.

Mol Clin Oncol. 2017 Oct;7(4):604-608. doi: 10.3892/mco.2017.1359. Epub 2017 Aug 3.

4.

Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.

Miyauchi E, Inoue A, Usui K, Sugawara S, Maemondo M, Saito H, Fujita Y, Kato T, Suzuki T, Harada T, Watanabe H, Nakagawa T, Ichinose M.

Oncologist. 2017 Jun;22(6):640-e59. doi: 10.1634/theoncologist.2017-0059. Epub 2017 May 19.

5.

The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease.

Yasuda Y, Hattori Y, Tohnai R, Ito S, Kawa Y, Kono Y, Urata Y, Nogami M, Takenaka D, Negoro S, Satouchi M.

Jpn J Clin Oncol. 2018 Jan 1;48(1):89-93. doi: 10.1093/jjco/hyx142.

PMID:
29036303
6.

Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report.

Niwa H, Otani S, Nakada N, Sasaki J, Saka H, Masuda N.

Respir Med Case Rep. 2018 Feb 2;23:131-135. doi: 10.1016/j.rmcr.2018.01.006. eCollection 2018.

7.

The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.

Fujita T, Hiroishi T, Shikano K, Yanagisawa A, Hayama N, Amano H, Nakamura M, Hirano S, Tabeta H, Nakamura S.

Intern Med. 2018 Jul 1;57(13):1827-1832. doi: 10.2169/internalmedicine.0404-17. Epub 2018 Feb 9.

8.

A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.

Hasegawa T, Futamura Y, Horiba A, Yoshida T, Suzuki T, Kato T, Kaito D, Ohno Y, Iida T, Hayashi S, Sawa T.

J Radiat Res. 2016 Jan;57(1):50-4. doi: 10.1093/jrr/rrv062. Epub 2015 Oct 5.

9.

A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.

Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, Yablonsky PK, Bhar P, Iglesias J.

J Thorac Oncol. 2010 Jun;5(6):852-61.

10.

[Efficacy and Safety of Carboplatin/Nanoparticle Albumin-Bound Paclitaxel Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer or Recurrent Non-Small-Cell Lung Cancer Following Surgery].

Shimabukuro I, Noguchi S, Uyama K, Torii R, Ishimoto H, Yoshii C, Tanaka F, Yatera K, Mukae H.

Gan To Kagaku Ryoho. 2018 Sep;45(9):1305-1310. Japanese.

PMID:
30237372
11.

Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.

Sekine A, Satoh H, Baba T, Ikeda S, Okuda R, Shinohara T, Komatsu S, Hagiwara E, Iwasawa T, Ogura T, Kato T.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1245-52. doi: 10.1007/s00280-016-3040-8. Epub 2016 Apr 29.

PMID:
27130459
12.

A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.

Okuma Y, Hosomi Y, Takahashi S, Nakahara Y, Watanabe K, Nagamata M, Takagi Y, Mikura S.

Cancer Chemother Pharmacol. 2016 Aug;78(2):383-8. doi: 10.1007/s00280-016-3092-9. Epub 2016 Jun 23.

PMID:
27339149
13.

A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.

Hanibuchi M, Kakiuchi S, Atagi S, Ogushi F, Shimizu E, Haku T, Toyoda Y, Azuma M, Kondo M, Kawano H, Otsuka K, Sakaguchi S, Nokihara H, Goto H, Nishioka Y.

Lung Cancer. 2018 Nov;125:93-99. doi: 10.1016/j.lungcan.2018.09.007. Epub 2018 Sep 12.

PMID:
30429044
14.
15.

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF.

J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30.

PMID:
22547591
16.

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.

Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H, Renschler MF.

Ann Oncol. 2013 Sep;24(9):2390-6. doi: 10.1093/annonc/mdt235. Epub 2013 Jul 10.

PMID:
23842283
17.

Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.

Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T.

Cancer Chemother Pharmacol. 2017 Jan;79(1):165-171. doi: 10.1007/s00280-016-3217-1. Epub 2016 Dec 19.

PMID:
27995307
18.

Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Yasuda Y, Nomizo T, Ozasa H, Funazo T, Tsuji T, Yoshida H, Sakamori Y, Nagai H, Handa T, Kubo T, Kim YH.

Mol Clin Oncol. 2017 Oct;7(4):677-680. doi: 10.3892/mco.2017.1373. Epub 2017 Aug 11.

19.

Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.

Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA.

Clin Lung Cancer. 2015 Nov;16(6):466-74. doi: 10.1016/j.cllc.2015.05.004. Epub 2015 May 13.

20.

Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons.

Higuchi M, Takagi H, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Yonechi A, Osugi J, Hoshino M, Shio Y, Fujiu K, Kanno R, Ohishi A, Suzuki H, Gotoh M.

Oncol Lett. 2017 Jun;13(6):4315-4321. doi: 10.3892/ol.2017.5998. Epub 2017 Apr 5.

Supplemental Content

Support Center